Vaxine expects to start Phase II trials for potential COVID-19 vaccine in weeks

Divya Chowdhury
·2 min read
FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration

By Divya Chowdhury

(Reuters) - Australian biotechnology company Vaxine Pty Ltd expects to start Phase II trials of its potential COVID-19 vaccine in the next few weeks after "positive" results from the first stage human study, chairman Nikolai Petrovsky said on Wednesday.

Final stage trials could start within the next three months, he told the Reuters Global Markets Forum chat room in an exclusive interview.

"It's extremely safe and well-tolerated. We already have that data from the clinical trial. We've not had any bad reactions to the vaccine. That's very positive," he said.

The company is working with South Korea's MedyTox, according to the World Health Organization's list of candidate vaccines. Human trials on 40 people started this month.

No vaccine has yet been approved for COVID-19, the disease caused by the new coronavirus that has killed more than 659,000 people and unleashed economic havoc worldwide.

Vaxine's shot is one of more than two dozen at the human clinical trial stage as the race to tame the pandemic heats up.

Petrovsky said two years is a realistic but ambitious time frame to get a COVID-19 vaccine to market, underscoring the challenge facing the global drugs industry to help control the virus.

"We may have vaccines that look effective after one year, but to then manufacture billions of doses and get them to people, I think everybody expects two years," he said.

"If you look at measles and polio, where there was a desperate urgency, it still took 4-5 years to develop an effective vaccine."

In terms of pricing, Petrovsky said COVID-19 vaccines could potentially cost between $20 to $200 per dose, depending on the technology's manufacturing cost. He said more effective vaccines, or those with fewer or no side effects may sell at a higher price.

Pfizer's deal with the U.S. government to sell 100 million doses for $2 billion "indicates that the price for a very large volume of vaccine will be around $20, but potentially on the private market, it may be $40-$50 by the time you have mark-ups by chemists and you get to retail," Petrovsky said.

((This interview was conducted in the Reuters Global Markets Forum, a chat room hosted on the Refinitiv Messenger platform. Sign up here to join GMF: https://refini.tv/2LbSKPl))

(Reporting by Divya Chowdhury; Editing by Josephine Mason and Kirsten Donovan)